Clinical trials: Epithelial Tumor, Malignant
Lung Cancer
Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003281
- Testing
- paclitaxel, topotecan hydrochloride, radiation therapy
- Where
- 19 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage IV Non-small Cell Lung Cancer
Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastatic NSCLC
To investigate whether radiotherapy combined with drug therapy is beneficial to non- oligometastatic stage IV NSCLC
- Trial name
- NCT05176067
- Testing
- Thoracic Three-dimensional Radiotherapy
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guizhou Medical University
NSCLC, Advanced Solid Tumor
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
This is an open-label, dose-escalation and cohort expansion study to evaluate the safety and preliminary efficacy of YSCH-01 in subjects with pulmonary metastasis of advanced solid tumors and advanced non-small cell lung cancer…
- Trial name
- NCT07793500
- Testing
- YSCH-01
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-Melanoma Skin Cancer (NMSC), Basal Cell Carcinoma of Skin
The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark.
The goal of this observational study is to learn about the long-term effects of radiotherapy for people who were treated for non-melanoma skin cancer (NMSC) in the head and neck area.
- Conditions
- Non-Melanoma Skin Cancer (NMSC), Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma of the Skin
- Trial name
- DOSCA-2 (NCT07347392)
- Testing
- Follow-up visit at least two years after treatment
- Where
- Denmark
- Volunteers
- 2,900 people
- Sponsor
- University of Aarhus
Non-small-Cell Lung Carcinoma, Surgery
N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
The objective of this multicenter retrospective study is to compare overall survival in patients with stage IIIA-N2 NSCLC treated with neoadjuvant treatment and surgery versus definitive chemoradiation.
- Conditions
- Non-small-Cell Lung Carcinoma, Surgery, Stage IIIA-N2, Chemoradiation
- Trial name
- NCT02966769
- Testing
- Overall survival
- Where
- Spain
- Volunteers
- 294 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
The purpose of this study is to evaluate the activity of RO4929097 in renal cell carcinoma patients that have failed therapy with VEGF/VEGFR directed agents.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT01141569
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 4 sites in Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Breast Adenocarcinoma, Metastatic Breast Carcinoma
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma…
- Conditions
- Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT03432741
- Testing
- Belinostat, Carfilzomib, Copanlisib Hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Non-muscle-invasive Bladder Cancer
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer
- Trial name
- POTOMAC (NCT03528694)
- Testing
- Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG)
- Where
- 120 sites in Australia, Austria and 10 more
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Esophageal Squamous Cell Carcinoma
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma
Retrospective analysis of the presence and maturity of tertiary lymphoid structures in pathological sections of patients with esophageal squamous cell carcinoma after surgical treatment.
- Trial name
- NCT06241066
- Testing
- no-Intervention
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cirrhosis, Hepatocellular Carcinoma
Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma
In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Surveillance
- Trial name
- NCT04414956
- Testing
- AFP-L3, AFP, PIVKA-II
- Where
- 15 sites in South Korea
- Volunteers
- 1,418 people
- Sponsor
- Korea University
Urothelial Carcinoma
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
- Trial name
- NCT01353222
- Testing
- DN24-02, Standard of Care
- Where
- 60 sites in United States
- Volunteers
- 142 people
- Sponsor
- Dendreon
Non-Small Cell Lung Cancer
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
- Trial name
- NCT00633529
- Testing
- IMO-2055
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
Hepatocellular Carcinoma, Liver Carcinoma
the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma
This study aimed to evaluate whether nutritional optimization-led triple prehabilitation could improve perioperative nutritional status, promote postoperative recovery, and reduce postoperative complications in patients with…
- Conditions
- Hepatocellular Carcinoma, Liver Carcinoma, Hepatobiliary Cancers, Primary Liver Cancer
- Trial name
- NCT06549829
- Testing
- Nutritional optimization-led triple prehabilitation Intervention, Conventional triple prehabilitation Intervention
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ovarian Cancer
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006453
- Testing
- carboplatin, gemcitabine hydrochloride
- Where
- 74 sites in United States, Canada
- Sponsor
- AGO Study Group
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
Squamous Cell Carcinoma of the Head and Neck
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN
The purpose of this study was to identify which cancer-related genes are turned on or turned off in order to determine how well a patient will respond to the study drug, panitumumab.
- Trial name
- TOP0901 (NCT01305772)
- Testing
- Panitumumab, Surgery, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Neal Ready
Ovarian Epithelial Cancer
Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the…
- Trial name
- CLIO (NCT02822157)
- Testing
- Olaparib, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
- Where
- Belgium
- Volunteers
- 160 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma
The purpose of this study is to understand the side effects (skin reaction, infection and abscess formation) at the site of radiation treatment, which my occur during the treatment and following 2 months using a new method of…
- Trial name
- NCT00165581
- Testing
- High Dose Intracavitary Brachytherapy
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Fallopian Tube Cancer
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- SIGNAL (NCT04368130)
- Testing
- SIGNAL
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Lung Adenocarcinoma
Lymph Node Pathologic Grading Strategy
The percentage of high-grade patterns in metastatic LNs (mLNs) that can predict poor outcomes has yet to be determined. Additionally, the potential implications of other histologic patterns in metastatic lymph nodes on patient…
- Trial name
- NCT06745830
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,998 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.